索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]周健,管翔,陈志远,等.新型抗凝药物在体外膜肺氧合中的应用进展[J].国际心血管病杂志,2021,06:349-351,359.
点击复制

新型抗凝药物在体外膜肺氧合中的应用进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年06期
页码:
349-351,359
栏目:
综述
出版日期:
2021-12-01

文章信息/Info

Title:
-
作者:
周健; 管翔; 陈志远; 李庆国
210000 南京医科大学第二附属医院心内科
Author(s):
-
关键词:
新型抗凝药物;  比伐卢定;  阿加曲班;  体外膜肺氧合
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.06.008
文献标识码:
-
摘要:
体外膜肺氧合(ECMO)在危重症患者抢救中的应用日益广泛,ECMO支持期间需要常规使用普通肝素(UFH)抗凝,但是抗凝不当可导致出血及血栓并发症。新型抗凝药物比伐卢定、阿加曲班等发展迅速,已有多项研究表明其替代UFH的潜在可能性。该文主要介绍ECMO支持期间凝血系统的改变、不同的抗凝监测手段,阐述ECMO支持期间UFH及新型抗凝药物应用现况,以进一步评估新型抗凝药物的安全性及发展前景。
Abstract:
-

参考文献/References

[1] Rajan S, Wissenberg M, Folke F, et al. Association of bystander cardiopulmonary resuscitation and survival according to ambulance response times after out-of-hospital cardiac arrest[J]. Circulation, 2016, 134(25):2095-2104.
[2] Guglin M, Zucker MJ, Bazan VM, et al. Venoarterial ECMO for adults: JACC scientific expert panel[J]. J Am Coll Cardiol, 2019, 73(6):698-716.
[3] Crowther M, Crowther M. Management of bleeding in patients on antithrombotics: maintaining the balance between thrombosis and hemorrhage[J]. Expert Rev Hematol, 2009, 2(4):357-360.
[4] Winkler AM. Managing the precarious hemostatic balance during extracorporeal life support: implications for coagulation laboratories[J]. Semin Thromb Hemost, 2017, 43(3):291-299.
[5] Dornia C, Philipp A, Bauer S, et al. Visualization of thrombotic deposits in extracorporeal membrane oxygenation devices using multidetector computed tomography: a feasibility study[J]. ASAIO J, 2013, 59(4):439-441.
[6] Wilm J, Philipp A, Müller T, et al. Leukocyte adhesion as an indicator of oxygenator thrombosis during extracorporeal membrane oxygenation therapy[J]. ASAIO J, 2018, 64(1):24-30.
[7] Lehle K, Philipp A, Gleich O, et al. Efficiency in extracorporeal membrane oxygenation-cellular deposits on polymethylpentene membranes increase resistance to blood flow and reduce gas exchange capacity[J]. ASAIO J, 2008, 54(6):612-617.
[8] Mazzeffi MA, Tanaka K, Roberts A, et al. Bleeding, thrombosis, and transfusion with two heparin anticoagulation protocols in venoarterial ECMO patients[J]. J Cardiothorac Vasc Anesth, 2019, 33(5):1216-1220.
[9] Hohlfelder B, Kelly D, Hoang M, et al. Activated clotting times demonstrate weak correlation with heparin dosing in adult extracorporeal membrane oxygenation[J]. Am J Ther, 2019.
[10] Belk KW, Laposata M, Craver C. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin[J]. J Thromb Haemost, 2016, 14(11):2148-2157.
[11] Panigada M, E Iapichino G, Brioni M, et al. Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study[J]. Ann Intensive Care, 2018, 8(1):7.
[12] Sakr Y. What’s new about heparin-induced thrombocytopenia type Ⅱ[J]. Intensive Care Med, 2015, 41(10):1824-1827.
[13] Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2 Suppl):e495S-e530S.
[14] Wood KL, Ayers B, Gosev I, et al. Venoarterial-extracorporeal membrane oxygenation without routine systemic anticoagulation decreases adverse events[J]. Ann Thorac Surg, 2020, 109(5):1458-1466.
[15] Krueger K, Schmutz A, Zieger B, et al. Venovenous extracorporeal membrane oxygenation with prophylactic subcutaneous anticoagulation only: an observational study in more than 60 patients[J]. Artif Organs, 2017, 41(2):186-192.
[16] Steg PG, van’t Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI[J]. N Engl J Med, 2013, 369(23):2207-2217.
[17] Stone GW, Mehran R, Goldstein P, et al. Bivalirudin versus heparin with or without glycoprotein Ⅱb/Ⅲa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials[J]. J Am Coll Cardiol, 2015, 65(1):27-38.
[18] Bates SM, Weitz J. The mechanism of action of thrombin inhibitors[J]. J Invasive Cardiol, 2000, 12(Suppl F):27-32.
[19] Sanfilippo F, Asmussen S, Maybauer DM, et al. Bivalirudin for alternative anticoagulation in extracorporeal membrane oxygenation: a systematic review[J]. J Intensive Care Med, 2017, 32(5):312-319.
[20] Pieri M, Agracheva N, Bonaveglio E, et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study[J]. J Cardiothorac Vasc Anesth, 2013, 27(1):30-34.
[21] Gladwell TD. Bivalirudin: a direct thrombin inhibitor[J]. Clin Ther, 2002, 24(1):38-58.
[22] Walker EA, Roberts AJ, Louie EL, et al. Bivalirudin dosing requirements in adult patients on extracorporeal life support with or without continuous renal replacement therapy[J]. ASAIO J, 2019, 65(2):134-138.
[23] Keyl C, Zimmer E, Bek MJ, et al. Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia[J]. Thromb Haemost, 2016, 115(6):1081-1089.
[24] Dingman JS, Smith ZR, Coba VE, et al. Argatroban dosing requirements in extracorporeal life support and other critically ill populations[J]. Thromb Res, 2020, 189:69-76.
[25] Menk M, Briem P, Weiss B, et al. Efficacy and safety of argatroban in patients with acute respiratory distress syndrome and extracorporeal lung support[J]. Ann Intensive Care, 2017, 7(1):82.
[26] Bachler M, Hell T, B?sch J, et al. A prospective pilot trial to assess the efficacy of Argatroban(Argatra)in critically ill patients with heparin resistance[J]. J Clin Med, 2020, 9(4):963.
[27] Zhong H, Zhu ML, Yu YT, et al. Management of bivalirudin anticoagulation therapy for extracorporeal membrane oxygenation in heparin-induced thrombocytopenia: a case report and a systematic review[J]. Front Pharmacol, 2020, 11:565013.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81670421); 江苏省社会发展重点研发专项(BE2016798)
通信作者:李庆国,E-mail:Lqg0235062@163.com
更新日期/Last Update: 2021-12-01